RU2264456C1 - Probiotic biopreparation for treatment of various infections and disbiosis and method for therapy of infections and disbiosis - Google Patents

Abstract

FIELD: biotechnology, medicine.

SUBSTANCE: claimed probiotic biopreparation contains living culture of bifidobacterium strain Bifidobacterium adolescectis in titre of 10⁵-10¹¹ CFU/ml (CFU - colony forming units) and bifidobacterium metabolism products having high bifidogenic effect. Particularly metabolism products include arabinofuranohydrolase, alpha-galactose, proteinase, protein-polysaccharide complex, alkaline protease and dextranase. They are characterized by drooping curve with change at 235-245 nm and maximum at 266±2 nm in ultraviolet absorption spectrum in wave length of 205-400 nm and dilution of 1:100. Metabolism products are cultivated for 16-18 h in broth containing stabilizer in amount of 30-50 vol.%. As stabilizer mixture containing (mass %): gelatin 9.0-12.0; sucrose 0.5-0.7 %; ascorbic acid 0.5-1.0, and balance: water is used. Method for therapy of various infections and disbiosis includes administrating to patient effective amount of abovementioned biopreparation.

EFFECT: improved preparation for treatment of infections and disbiosis.

5 cl, 5 dwg, 5 tbl, 7 ex

Description

The invention relates to biotechnology and medicine, and relates to the development of a probiotic for the treatment of infectious diseases, dysbiosis of various etiologies and a method for treating these diseases using a new probiotic.

Bacterial preparations are known - probiotics containing live bifidobacteria that inhibit the growth of pathogenic and conditionally pathogenic bacteria. These biological products are widely used for the treatment and prevention of dysbiosis and intestinal dysfunctions, and other infectious diseases, for example, for the treatment of non-specific bacterial vaginosis, correction of the microflora of the birth canal, and prevention of mastitis.

Known bacterial preparation bifidumbacterin dry, containing a dried culture of B.bifidum 1 in a protective environment (Schedule for the production of bifidumbacterin No. 557-96).

Dry bifidumbacterin, obtained by this technology, is widely used in medical practice. However, the disadvantage of this drug is the low content of live bifidobacteria in a dose. In addition, the composition of the drug includes biomass freed from metabolites, as a result of which bifidobacteria quickly lose their viability, which reduces the stability and effectiveness of the drug.

A known method for the treatment and prevention of infectious diseases, including non-specific bacterial vaginosis, mastitis, correction of the microflora of the birth canal, dysbiosis and intestinal dysfunction using dry bifidumbacterin (Goncharova G.I., Semenova L.P., Kozlova E.P., etc. The use of dry bifidumbacterin in the complex treatment of premature and full-term infants and young children: Methodological recommendations. M. - 1988).

However, due to the insufficient effectiveness of bifidumbacterin in the treatment of acute intestinal infections (AEI) and dysbiosis, it should be taken for a long time (3-4 weeks), and in order to obtain a stable recovery of normoflora, it is necessary to use the drug in several courses for up to 3-4 months.

Known biological product Bifidumbacterin, containing a lyophilized suspension of bacteria of strain B. bifidum 1. in a nutrient medium with the addition of a protective sucrose-gel-milk drying environment with ascorbic acid or cysteine (SU No. 1364341, publ. 07.01.1988).

The disadvantage of the drug is the need for prolonged use to achieve a stable bacteriological effect and slow correction of local immunity, especially in debilitated patients.

The disadvantage of this drug is also the low efficiency and long treatment time.

Also known is the bifidumbacterin preparation containing a lyophilized culture of B. bifidum 791 strain in a drying medium based on milk, gelatin and sucrose. The drug is intended for the complex treatment of gastrointestinal diseases, pneumonia, sepsis and other purulent-infectious diseases (Patent RU No. 2072856, A 61 K 35/74, publ. 02/10/1997).

The disadvantage of the drug is the loss during centrifugation of the target product, because metabolites of bifidobacteria go away with the separated culture fluid, the absence of which negatively affects the survival of bacteria during drying and storage.

Also known is the probiotic bifidumbacterin forte, containing the lyophilized biomass of bifidobacteria, the bifidogenic component is lactose or fructooligosaccharide, the immobilizer is activated carbon, dietary fiber or kaolin, as well as a protective drying environment from gelatin and sucrose. The dosage form is in the form of tablets or capsules coated with a gastro-resistant coating of shellac or cellulose acetate. A known method of treating acute and chronic intestinal diseases, including the introduction of a probiotic bifidumbacterin form according to the scheme: on the first day - 4-40 g, after 12 hours 4-12 g, on the second day - 4-18 g, on the 3rd day 4- 12 g, on the 4th and subsequent days - 3-9 g (Patent RU No. 2164143, A 61 K 35/74, publ. 20.03.2001).

The disadvantage of this drug is contraindications for lactopathy.

The closest analogue is a biological product - the Ecoflor probiotic in dry immobilized form containing a sorbent, eubiotic cells - bifidobacteria in a titer of 10 ⁸ -10 ¹⁰ CFU / g, immobilized on a sorbent, and a protective medium based on gelatin, ascorbic acid, sodium chloride and sucrose, and the cells of eubiotics are used in conjunction with a milk-based nutrient medium, and B. bifidum 1 or B. bifidum 791 or LVA-3 or B. longum 379 or B. adolescentis MC-42 or a mixture thereof are used from bifidobacteria (Patent RU No. 2164801, A 61 K 35/74, publ. 04/10/2001).

However, the composition of the biological product includes a milk-based environment, which is non-standard, and, as a rule, contains traces of antibiotics and hormones, which can cause side effects. In addition, the biological product has contraindications for administration: it is not recommended for lactosopathy, as well as for administration to weakened children, as sorbents adsorb B and C vitamins on their surface

The technical result of the invention is to create a drug that has no contraindications, which allows to reduce the time of treatment of the patient and increase the effectiveness of the treatment of dysbiosis of various etiologies due to improved adhesive properties and colonization, increased activity against pathogenic and conditionally pathogenic microorganisms of the causative agent of gastrointestinal diseases, stimulation of non-specific resistance , reduce the consumption of antibiotics in the treatment and prevention of a number of intestinal infections.

The invention consists in the following.

The biopreparation - probiotic Bifidin contains a live culture of the bifidobacterium strain Bifldobacterium adolescentis МС-42 in a titer of 10 ⁵ -10 ¹¹ CFU / ml and their vital products, obtained by culturing for 16-18 hours on a nutrient medium in which a stabilizer of 30- 50% of the volume of the medium, and characterized by a falling curve with an inflection in the region of 235-245 nm and a maximum of 266 ± 2 in the ultraviolet absorption spectrum in the wavelength range of 205-400 nm at 1: 100 dilutions.

Gelatin, sucrose, ascorbic acid are used as stabilizer in the following ratios of components, wt.%: Gelatin - 9.0-12.0; ascorbic acid - 0.5-1.0; sucrose - 0.5-0.7%; water - the rest, up to 100%.

Biological product Bifidin can be in liquid form or freeze-dried.

A specific feature of the biological product, the probiotic Bifidin, is that in addition to the biomass of bifidobacteria, it contains vital products of bifidobacteria with a pronounced bifidogenic effect.

It was established that during the growth of the culture of B. adolescentis MS-42 on a nutrient medium into which a stabilizer was added in an amount of 30-50% of the volume of the medium, during incubation for 16-18 hours at a temperature of (38 ± 1) ° С, a significant accumulation of polyphosphate inclusions (volutin), protein-polysaccharide complex (BOD), alkaline protease and dextranase in cells and culture fluid. In addition, the strain produces specific enzymes: arabinofuranohydrolase, α-galactose, proteinase, responsible for important physiological and biological processes in food varietal tract.

These cultivation conditions of the strain lead to a high intensity of metabolic processes and, consequently, a significant protective effect, in particular, inhibition of the growth of pathogenic and conditionally pathogenic microorganisms.

The fractional composition of the ultrafiltrate of the biological product Bifidin was studied by gel chromatography on Sephadex G-75 and Sephadex G-25 (Figs. 1 and 3). For comparison, the fractional composition of the ultrafiltrate of the biological product Bifidumbacterin was studied (Fig. 2 and 4). The results indicate that Bifidin ultrafiltrate contains a monomer fraction with a molecular weight of at least 1450 KDa, which is not detected in Bifidumbacterin ultrafiltrate.

The ultraviolet absorption spectrum of a biological product Bifidin was studied on an SF-46 spectrophotometer in the wavelength range of 205-400 nm at various dilutions of the biological product ultrafiltrate.

The UV spectrum of the ultrafiltrate of the biological product Bifidin at 1: 100 dilutions is a falling curve with an inflection in the region of 235-245 nm and a maximum of 266 ± 2 (Fig. 5).

Bifidin has high clinical efficacy in the treatment of various acute intestinal infectious diseases, enteritis, colitis, including in infants.

The drug is prescribed to patients at 5 doses 2 times a day 30 minutes before meals, for 5-8 days.

Clinical trials conducted on patients with acute intestinal diseases (acute dysentery, salmonellosis, rotavirus gastroenteritis, Escherichiosis E. coli 0151, adenoviral disease with intestinal syndrome and foodborne toxicoinfections / IPT /), showed the following:

1. High clinical efficacy (the disappearance of intoxication, the cessation of abdominal pain, the normalization of stool by 3 days).

2. Elimination of the pathogen (especially resistant to antibiotics).

3. Sanitizing activity against pathogenic bacteria (in particular, salmonella).

4. After a short course of treatment, a positive dynamics in the intestinal microflora is observed.

The invention is illustrated by the following examples:

Example 1

Strain B. adolescentis MC-42 of the first passage was grown on an agar medium under anaerobic conditions for 42-48 hours at a temperature of 38 ± 1 ° C to obtain isolated colonies.

At the end of the incubation, smooth colonies are selected, which (at least 25-30 colonies) are seeded in an adequate liquid nutrient medium / 2 passage /.

The 2nd passage is subcultured into the optimal nutrient medium / 3rd passage /. The 4th passage is seeded in any liquid nutrient medium suitable for culturing bifidobacteria, for example, Blaurock medium or casein-yeast medium (KD-5 medium), to which a stabilizer is added in an amount of 30-50% by volume. As a stabilizer, gelatin, sucrose, ascorbic acid are used at component ratios, wt.%: Gelatin - 10.0; ascorbic acid - 1.0; sucrose - 0.7; water - the rest is up to 100%.

The B. adolescentis MC-42 culture was incubated for 16-18 hours at a temperature of (38 ± 1) ° С. During this time, there is a significant accumulation of polyphosphate inclusions (volutin), VPA, alkaline protease and dextranase, arabinofuranohydrolase, α-galactose, and proteinase in cells and culture fluid.

To obtain a liquid form, the preparation is Packed in 5 ml in bottles under rubber stoppers and rolled.

To obtain a freeze-dried form, the preparation is packaged in 5 ml vials, freeze-dried, closed with rubber stoppers and rolled.

Example 2. Obtained in example 1, the probiotic Bifidin is tested for bactericidal activity. As a control, the probiotic Bifidumbacterin (manufactured according to the Bifidumbacterin Production Regulation No. 557-96) is used.

The sensitivity of test strains (S.aureus 209, S.aureus 3CH, E.fecalis 115CH, E.coli 22CH, Enterobacter ss p No. 3CH) to biological products of various variants is studied by diffusion method.

On the surface of the nutrient medium in Petri dishes, 1-2 ml of a bacterial suspension (10 ⁹ CFU / ml) is applied. Excess liquid is removed with a pipette. After drying the plates, filter paper disks impregnated with the studied biological products are placed on the agar surface.

Bifidin and control are examined in dilutions - outgoing .; 1: 2; 1: 5. Crops are incubated at 37 ° C for 24 hours.

The sensitivity of crops to biological products is expressed in mm of the diameter of the zones of growth inhibition. Resistant strains are considered, growth retardation zones of which are 0-8 mm; sensitive - 9-18 mm; highly sensitive - more than 18 mm. The results are presented in table. 1.

The study revealed that Bifidin has a high bactericidal activity to strains of staphylococcus and enterococcus at a dilution of 1: 5, to strains of E. coli and enterobacter - 1: 2, while Bifidumbacterin was active only in the initial dilutions (Table 1).

Example 3. The effect of drugs on opportunistic bacteria is determined by the method of serial dilutions in a liquid medium Gause No. 2.

3 ml of Bifidin or the well-known probiotic Bifidumbacterin are added to a first test tube with 3 ml of liquid medium.

After mixing the suspension with a pipette at least 10 times, a series of 2-fold dilutions is carried out. The pipettes are changed after each dilution. 0.2 ml of bacterial suspension of test strains (S.aureus 209, E.fecalis 115CH or Candida albicans 5CH) are added to the obtained dilutions of biological preparations. The concentration of bacteria corresponds to 5 units. industry standard turbidity sample GISK named after L.A. Tarasevich (OSO 42-28-59-85).

To control the growth of the culture, 0.2 ml of the test strain is inoculated, corresponding to 5 units. industry standard sample, in (3 ± 0.1) ml for titration. The results are taken into account after (20 ± 2) h after incubation of the culture at a temperature of (36 ± 1) ° С.

The titer of the biological product is set in a test tube with the highest dilution of the drug, in which the absence of growth of the test strain was visually noted.

It was found that Bifidin better inhibits the growth of staphylococci and enterococci in a dilution of 1:64, Candida fungi - 1: 8, while in the control (probiotic Bifidumbacterin) - 1: 8 and 1: 4, respectively (Table 2).

Thus, it was shown that the drug Bifidin exhibits a higher bactericidal activity compared with the drug Bifidumbacterin.

Example 4. The study of the antagonistic activity of Bifidin and the commercial drug Bifidumbacterin is carried out in relation to conditionally pathogenic microorganisms isolated from patients with dysbiosis of various etiologies.

On the dried Petri dishes with MPC-5 medium, the studied culture of the preparation is streaked with a loop diameter of 3.5 ± 0.5 mm. Crops are incubated in an incubator at 37 ± 1 ° C for 72 hours in an anaerostat. Then, retreating 1 mm from the grown culture, test strains were seeded with a perpendicular stroke.

The results are taken into account after 18 hours of incubation at 37 ± 1 ° C according to the size of the zones of inhibition of growth of test strains (measuring these zones with a ruler: from the test culture to the beginning of growth of test cultures in mm). Control of the growth of test cultures is their parallel seeding by stroke on plates with the same medium.

The results of the study of the antagonistic effect of drugs on facultative aerobes are presented in table 3.

As can be seen from the obtained data, Bifidin is characterized by a more pronounced antagonistic activity against clinical strains of Shigella, Salmonella, Staphylococcus, Streptococcus compared with the control (Bifidumbacterin drug). Clinical strains of fungi of the genus Candida were resistant to lactic acid bacteria (Table 3).

Thus, the obtained data on antagonistic activity indicate the advantage of the drug Bifidin compared with Bifidumbacterin.

Example 5. Tests of the drug Bifidin were conducted in the clinical department of the Moscow Scientific Research Institute of Power Engineering named after G.N.Gabrichevsky on the basis of the 1st city clinical infectious diseases hospital in adult 52 patients, with acute dysentery, salmonellosis and escherichiosis.

At the same time, under the same conditions, observations were made in the comparison group of 42 patients receiving commercial Bifidumbacterin. The etiological structure and nature of the course of diseases in the comparison group were similar to those in the main group. In both groups, patients with a moderate course of intestinal infection predominated.

Biological products Bifidin (in the main group) and Bifidumbacterin (in the comparison group) were prescribed to patients with acute intestinal infections at 5 doses 2 times a day, the course of treatment was 7-8 days. No side effects were noted in any case.

The effectiveness of treatment was determined by the timing of the disappearance of intoxication, the cessation of abdominal pain and the normalization of stool in days from the moment of admission to the hospital, as well as the results of studies of intestinal microflora for dysbiosis.

As can be seen from the data presented in Table 4, for all clinical indicators, Bifidin was not inferior to commercial Bifidumbacterin, and in terms of stool normalization, it contributed to a more pronounced positive dynamics compared to Bifidumbacterin.

In patients with acute intestinal infections, Bifidin, to a greater extent than Bifidumbacterin, has a positive effect on the intestinal microflora. Thus, the incidence of dysbacteriosis of the III-IV degree, detected in the main group before treatment in 80.0 ± 11.2% of patients, decreases after application of Bifidin to 55.0 ± 9.7%, i.e. more than 20%. In the comparison group, with the initial frequency of dysbiosis of the same degree of 61.5 ± 9.2%, its decrease after the use of Bifidumbacterin occurs up to 53.8 ± 6.9%, i.e. almost 8%.

It was noted with certainty that in the group of patients receiving Bifidin, there was a more pronounced increase in the number of bifidobacteria: from 4.3 ± 0.4 lg to, 1 ± 0.7 lg compared to the group receiving Bifidumbacterin, where the indicators were, respectively, from 6.4 ± 0.6 log to 6.8 ± 0.7 log. In addition, the number of conditionally pathogenic microbes significantly decreased in those receiving Bifidin: from 3.2 ± 0.3 lg to 1.4 ± 0.014 lg, while in those receiving Bifidumbin these indicators remained almost at the initial level: 5.0 ± 0, 5 and 5.4 ± 0.5 log before and after treatment (Table 5).

Thus, Bifidin was not inferior to commercial Bifidumbacterin in pronounced clinical efficacy, and even exceeded it in terms of its effect on the restoration of bifidoflora and elimination of conditionally pathogenic microorganisms.

Example 6. Bifidin was used in children suffering from acute intestinal infections (105 people), mainly salmonellosis patients predominated. In the case of an unknown etiology, the disease was characterized by gastroenterocolitis or enterocolitis.

By the time Bifidin was prescribed, intestinal disorders persisted in 41 children in the form of rapid fluid stool with pathological impurities (mucus, green staining). In 12 children, after salmonellosis, salmonella secretion continued when the stool was formed. Among patients with intestinal disorders, children with a protracted course of the disease predominated, receiving unsuccessfully (before prescribing Bifidin) antibacterial and / or other bacterial preparations (mainly bifidumbacterin).

The drug was prescribed 5 doses 2 times a day, for 7-10 days. Occasionally (in no more than 10-15% of cases) with a protracted process, Bifidin was continued for up to 2 weeks.

At the same time, under the same conditions, observations were made in a comparison group of 45 children receiving commercial bifidumbacterin. The etiological structure and nature of the course of diseases in the comparison group were similar to those in the main group. A comparison group according to the age composition of patients was comparable with the experimental one. Bifidumbacterin was prescribed 5 doses 2 times a day for 2 weeks.

All children tolerated Bifidin well, there were no allergic reactions, there was no increase in the number of eosinophils in the peripheral blood, there were no adverse reactions to taking Bifidumbacterin, only 2 out of 22 patients showed a slight increase in the number of eosinophils in the peripheral blood (from 5 to 10% )

By the end of the course of treatment with Bifidin, stool returned to normal in 56.1% of patients, while the rest showed an improvement in the nature of bowel movements, their reduction, reduction or disappearance of pathological impurities. As a result of using Bifidumbacterin, stool normalization was achieved in 50% of patients; an improvement in the nature of bowel movements and a decrease in the frequency of bowel movements was noted in 38.1%; the effect was absent in 11.9% of patients. At the end of the course of treatment with Bifidumbacterin, 24.4% due to insufficient effect, the therapy was continued with other biological products.

Studies of intestinal microflora revealed a normalizing effect of both drugs on the content of Escherichia coli, but in the control group the number of hemolytic forms remained unchanged. In the group of children who used Bifidin, an increase in the content of bifidobacteria was recorded.

The sanitizing activity of Bifidin against salmonella was revealed. The appointment of Bifidin to 12 children from the observed group, who secreted Salmonella with stool after infection, led to the elimination of the pathogen in 58.3%.

Thus, in children with acute respiratory infections, according to clinical and laboratory parameters, Bifidin was not inferior to commercial Bifidumbacterin and turned out to be somewhat more active in stimulating effect on bifidoflora (an increase in the frequency of seeding of bifidobacteria by 25% compared with the detection in Bifidumbacterin - 18%). It is also important to note that the discussed positive results were achieved from the use of Bifidin after a shorter course of treatment (7-10 days) than after the use of Bifidumbacterin (14 days).

Example 7. Bifidin was used as a means of restorative bacterial therapy, in combination with restorative, sedative and desensitizing drugs in 20 patients with non-specific recurrent or continuous ulcerative colitis. The drug was used in 5 doses 2 times a day for 10 days. The comparison group consisted of 20 patients with ulcerative colitis who received the commercial drug Bifidumbacterin, also against the background of basic complex therapy. According to the age composition, sex, form and severity of the disease, the comparison group corresponded to the main observed group treated with Bifidin. The course of treatment with bifidumbacterin was also 10 days at the same daily dosage.

Data on the clinical efficacy of Bifidin allow us to say that a 10-day course of taking the drug leads to: the disappearance of spasm of the colon, bloating, flatulence; normalization of temperature - up to 36.7 ° C compared with 37.2 ° C at the beginning of treatment (in patients with prolonged subfebrile condition); an increase in body weight by an average of 1.3 kg (no weight loss), a decrease in the frequency of stool. It was established that while taking Bifidin, normalization of the microflora composition was detected in 83.3% of patients receiving Bifidin, and in 67.2% of patients taking Bifidumbacterin. At the same time, the titer of lacto- and bifidobacteria, enterococci, and lactococci in patients taking Bifidin was 6.8 lg / ml, and after bifidumbacterin - 5.1 lg / ml.

The ratio between microflora with fermentation and respiratory metabolism was 15 / 0.2 in patients taking Bifidin and 14.9 / 1.2 after taking Bifidumbacterin. The ratio in% between coccal flora and rod was 19/81 after taking Bifidin and 29/71 in patients receiving Bifidumbacterin. Staphylococcus aureus titer after taking Bifidin decreased to 0.8 lg / ml compared to 2.3 lg / ml before treatment, and after taking Bifidumbacterin it was 1.4 lg / ml compared to 2.2 lg before treatment. Proteus titer was 0.2 lg / ml after taking Bifidin compared with 3.3 lg / ml before treatment, and after using Bifidumbacterin it was 0.8 lg / ml compared to 3.4 lg / ml before treatment.

Thus, as a result of the studies revealed a higher clinical and bacteriological effectiveness of Bifidin in the treatment of ulcerative colitis compared with commercial Bifidumbacterin.

Table 4 Dates of normalization of the main clinical indicators in adult patients with acute intestinal infections during treatment with Bifdin and commercial Bifidumbacterin Clinical indicators Drug name Number of patients Dates of normalization of the main clinical indicators in days (M ± m) Disappearance of intoxication Bifidine 39 3.2 ± 0.15 Bifidumbacterin 41 2.9 ± 0.10 Cessation of abdominal pain Bifidine 37 3.7 ± 0.31 Bifidumbacterin 32 3.9 ± 0.43 Stool normalization Bifidine 39 3.2 ± 0.22 Bifidumbacterin 42 3.9 ± 0.39 Table 5 The composition of the microflora of the large intestine in patients with acute intestinal infections before and after treatment with Bifidin and Bifidumbacterin Biological product Inspection Dates The amount of microflora in feces Ig CFU / ml Esherichia Bifidobacteria Lactobacilli Conditionally pathogenic microflora Bifidine Before treatment 8.2 ± 0.8 4.3 ± 0.4 2.2 ± 0.2 3.2 ± 0.3 After treatment 8.5 ± 0.8 7.1 ± 0.7 3.1 ± 0.3 1.4 ± 0.14 R ≥0.05 ≤0.05 ≤0.05 ≤0.05 Bifidumbacterin Before treatment 8.7 ± 0.9 6.4 ± 0.6 2.9 ± 0.3 5.0 ± 0.5 After treatment 8.4 ± 0.8 6.8 ± 0.7 2.7 ± 0.7 5.4 ± 0.5 R ≥0.05 ≥0.05 ≥0.05 ≥0.05

Claims (5)

1. A probiotic biological product for the treatment of infectious diseases and dysbioses of various etiologies, containing a live culture of the Bifidobacterium adolescentis MC-42 strain of bifidobacteria in a nutrient medium and a stabilizer, characterized in that it contains bifidobacteria in a titer of 10 ⁵ -10 ¹¹ CFU / ml and their vital products obtained during cultivation for 16-18 hours on a nutrient medium, to which a stabilizer was added in an amount of 30-50% of the volume of the medium, and characterized by a falling curve with an inflection in the region of 235-245 nm and a maximum of 266 ± 2 in the ultraviolet spectrum absorption in the wavelength range of 205-400 nm at dilutions of 1: 100. 2. The biological product according to claim 1, characterized in that it contains arabinofuranohydrolase, α-galactose, proteinase, protein-polysaccharide complex, alkaline protease and dextranase from the waste products. 3. The biological product according to claim 1, characterized in that gelatin, sucrose, ascorbic acid are used as stabilizer in the following component ratios, wt.%: Gelatin-9.0-12.0; ascorbic acid-0.5-1.0; sucrose-0.5-0.7%; water - the rest is up to 100%. 4. The biological product according to any one of claims 1 to 3, characterized in that it is freeze-dried. 5. A method for the treatment of infectious diseases and dysbioses of various etiologies by introducing a probiotic biological product to the patient based on a live culture of the Bifidobacterium.adolescentis MC-42 strain of bifidobacteria, characterized in that the biological product according to claim 1 is administered to the patient in an effective amount.

Images